Similarly, combining peripheral blood m6A modification levels with METTL14 and FTO regulatory genes achieved an AUC of 0.929 for breast cancer diagnosis, which was also better than the biomarkers CEA (0.599) and CA153 (0.572). Here, FTO is linked to breast cancer.